HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Reappointment of Statutory Auditors at the Meeting of the Board of Directors of HealthCare Global Enterprises Limited ('the Company') held on May 26, 2022. HealthCare Global Enterprises Ltd - 539787 - Earnings Call Held With Analysts/Investors To Discuss The Financial Results Of The Quarter And Year Ended March 31, 2022
Earnings Call held with Analysts/Investors to discuss the Financial Results of the quarter and year ended March 31, 2022 HealthCare Global Enterprises Ltd - 539787 - Statement Of Deviation March 31, 2022
Statement of Deviation_March 31, 2022 HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Investor Presentation
Updated Investor Presentation. Q4FY22 Quarterly Result Announced for Healthcare Global Enterprises Ltd.
Healthcare Global Enterprises announced Q4FY22 results: Q4FY22: Consolidated Income from Operations (“Revenue”) was Rs 3,646 Mn as compared to Rs 2,981 million in the corresponding quarter of the previous year, reflecting a YoY growth of 22.3% Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was Rs 661 million, as compared to Rs 438 million in the corresponding quarter of the previous year, a growth of 51.2% YoY Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was Rs 631 million, as compared to Rs 394 million in the corresponding quarter of the previous year, a growth of 60.4% YoY Operating EBITDA for Existing centers was Rs 610 million, a growth of 38.6% YoY, reflecting an Operating EBITDA margin of 22.0% Operating EBITDA from New centers was Rs 21 million, as compared to loss of Rs (46) million in the corresponding quarter of the previous year Proforma PAT was Rs 67 Mn, as compared to a loss of Rs (155) million in the corresponding quarter of last year, after adjusting below and tax implications there of; Onetime project fee of Q4’22 Rs 25 million ESOP Scheme expense of Q4’22 Rs 19 million FY22: Consolidated Income from Operations (“Revenue”) was Rs 13,978 million as compared to Rs 10,134 million in the previous year, reflecting a YoY growth of 37.9% Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”), was Rs 2,380 million, as compared to Rs 1,266 million in the corresponding quarter of the previous year, a growth of 88.0% YoY Operating EBITDA for Existing centers was Rs 2,308 million, reflecting an Operating EBITDA margin of 21.5% Operating EBITDA from New centers was Rs 72 million, as compared to loss of Rs (157) million in the previous year Proforma PAT was Rs (13) Mn, as compared to a loss of Rs (980) million in the previous year, after adjusting below and tax implications there of; Impairment of NCR project Rs 472 million Exceptional gain of Rs (1419) million arising out of Strand and Suchirayu acquisition Onetime project fee of FY’22 Rs 45 million ESOP Scheme expense of FY’22 Rs 55 million DTA recognized on tax expense through the year, on account of discontinuation of Kochi project, Rs (25) million Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “HCG has carved a niche as the cancer care destination of choice across all key areas of clinical, research, and academic excellence. Our phenomenal growth over the years bears testimony to the fact that cancer can be considered just like any other chronic disease, however curable. This year, we have added over 40 oncologists to our growing team which takes our doctor’s strength to over 450 which is the largest in the country in Oncology. We continue to employ the latest and most advanced techniques of cancer diagnosis and treatment enabling us to serve a greater number of patients with an objective of quality outcome. In a landmark development, we introduced Microsoft HoloLens, the next-gen holographic headset, heralding a new era of virtual reality at our enterprise. Through a pioneering industry initiative, we have brought healthcare training and medical education to the Metaverse by publishing 200+ hours of virtual reality content across multiple subspecialties. Patients are our most important stakeholders. To serve them more effectively, we have invested in a robust digital platform employing cutting-edge technologies for end-to-end patient engagement. The crux of our high quality of care across the length and breadth of the country is to ensure the right treatment, the very first time. Going forward, we believe our robust cancer care ecosystem will continue to deliver impressive returns. Cancer therapies are undergoing a defining change every 75 days. Thanks to our enhancement of knowledge and innovations, we are able to relentlessly manage the cancer care in a progressive way. Backed by our research labs and the clinical trials, we are uniquely positioned to enhance our diagnostic capabilities and offerings, as also redefine precision medicine with end-to-end expertise spanning bioinformatics, genomics and research. This will enable us to deliver tangible patient outcomes with greater precision over the long term. Academics and Research go hand in hand with patient care and our capabilities in this regard makes us the benchmark in cancer care treatment. We are happy to share that our Centre of Excellence in Bangalore has been ranked #1 in the country.” Result PDF HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release_Audited Financial Results_March 31, 2022 HealthCare Global Enterprises Ltd - 539787 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation on the financial results for the year ended March 31, 2022. HealthCare Global Enterprises Ltd - 539787 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting HealthCare Global Enterprises Ltd - 539787 - Audited Financial Results Of Healthcare Global Enterprises Limited For The Year Ended March 31, 2022
Audited Financial Results of HealthCare Global Enterprises Limited for the year ended March 31, 2022